- Keytruda — Merck’s Keytruda has been approved to treat triple-negative breast cancer in combination with chemotherapy. The drug has now been approved to treat 30 types of cancer.
- Bydureon — AstraZeneca’s Bydureon has been approved to treat Type 2 diabetes in pediatric patients ages 10 years and older.
- Rezurock — Kadmon Pharmaceuticals’ Rezurock has been approved to treat chronic graft-versus-host disease.
- Wegovy — Novo Nordisk’s Wegovy has been approved to treat obesity, the first new drug to treat the condition approved by the FDA in seven years.
- Rylaze — Jazz Pharmaceuticals’ Rylaze has been approved as a component of a chemotherapy regimen to treat acute lymphoblastic leukemia and lymphoblastic lymphoma in adult and pediatric patients who are allergic to the drugs used most commonly for treatment.
- Pradaxa — Boehringer Ingelheim’s Pradaxa has been approved to treat venous thromboembolism, a condition where blood clots form in the veins, in children 3 months to under 12 years old. It is the first FDA-approved blood-thinning medication that children can take by mouth.
- Astepro — Bayer’s Astepro, a nasal antihistamine, has been approved for nonprescription use. Astepro is approved to treat seasonal and perennial allergic rhinitis in adults and children over 6 years.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.